Evidence map›Paper›PMID 21500122›Full record

ReviewSeminars in respiratory and critical care medicine2011

Evolving concepts in lung carcinogenesis.

Brigitte N Gomperts, Avrum Spira, Pierre P Massion, Tonya C Walser, Ignacio I Wistuba, John D Minna, Steven M Dubinett

Abstract readReview
In one paragraph

Review in Seminars in respiratory and critical care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Epidemiological Study of Risk Factors for Lung Cancer in KwaZulu-Natal, South Africa.International journal of environmental research and public health · 2022
    Article
  9. Early Diagnosis and Screening for Lung Cancer.Cold Spring Harbor perspectives in medicine · 2021
    Review
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Gene Promoter Hypermethylation Detected in Sputum Predicts FEVAmerican journal of respiratory and critical care medicine · 2018
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Brigitte N GompertsDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA. bgomperts@mednet.ucla.edu
Avrum Spira
Pierre P Massion
Tonya C Walser
Ignacio I Wistuba
John D Minna
Steven M Dubinett
University of California, Los Angeles · USBoston University · USCenter for Neuro-Oncology · USThe University of Texas MD Anderson Cancer Center · USVanderbilt-Ingram Cancer Center

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
NCI NIH HHS P50 CA070907
6 · The paper itself

Abstract

Lung carcinogenesis is a complex, stepwise process that involves the acquisition of genetic mutations and epigenetic changes that alter cellular processes, such as proliferation, differentiation, invasion, and metastasis. Here, we review some of the latest concepts in the pathogenesis of lung cancer and highlight the roles of inflammation, the "field of cancerization," and lung cancer stem cells in the initiation of the disease. Furthermore, we review how high throughput genomics, transcriptomics, epigenomics, and proteomics are advancing the study of lung carcinogenesis. Finally, we reflect on the potential of current in vitro and in vivo models of lung carcinogenesis to advance the field and on the areas of investigation where major breakthroughs will lead to the identification of novel chemoprevention strategies and therapies for lung cancer.

Indexed as

AnimalsAnticarcinogenic AgentsEpigenesis, GeneticEpigenomicsGene Expression ProfilingGenomicsHigh-Throughput Nucleotide SequencingHumansInflammationLung NeoplasmsMutationNeoplastic Stem CellsProteomicsAnticarcinogenic Agents

Identifiers

PMID21500122
PMCPMC3423907
OpenAlexW2094286079

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.